



The Protein Sequencing Company™

Corporate Presentation

March 2023



Disclaimer

Cautionary Note Regarding Forward-Looking Statements

This presentation includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Actual results of Quantum-Si Incorporated (the “Company”) may differ from its expectations, estimates, and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions (or the negative versions of such words or expressions) are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, the Company’s expectations with respect to future performance, development of products and services, potential regulatory approvals, the size and potential growth of current or future markets for the Company’s future products and services, or the Company’s plans expectations or future operations, financial position, revenues, costs or expenses. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from those discussed in the forward-looking statements. Most of these factors are outside the Company’s control and are difficult to predict. Factors that may cause such differences include, but are not limited to: the impact of COVID-19 on the Company’s business; the inability to maintain the listing of the Company’s shares of Class A common stock on The Nasdaq Stock Market; the ability to recognize the benefits of the Company’s business combination, which may be affected by, among other things, competition and the ability of the Company to grow and manage growth profitably and retain its key employees; changes in applicable laws or regulations; the Company’s ability to raise financing in the future; the success, cost and timing of the Company’s product development activities; the potential attributes and benefits of the Company’s products and services; the Company’s ability to obtain and maintain regulatory approval for its products, and any related restrictions and limitations of any approved product; the Company’s ability to identify, in-license or acquire additional technology; the Company’s ability to maintain its existing lease, license, manufacture and supply agreements; the Company’s ability to compete with other companies currently marketing or engaged in the development of products and services that the Company is developing; the size and growth potential of the markets for the Company’s future products and services, and its ability to serve those markets, either alone or in partnership with others; the pricing of the Company’s products and services following commercial launch; the Company’s estimates regarding future expenses, future revenue, capital requirements and needs for additional financing; the Company’s financial performance; and other risks and uncertainties indicated from time to time in the Company’s filings with the U.S. Securities and Exchange Commission. The Company cautions that the foregoing list of factors is not exclusive. The Company cautions readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based.



Quantum-Si: The Protein Sequencing Company™



Experienced Team

From life sciences leaders including Illumina, Millipore Sigma, and Ion Torrent

185

Employees

Cash runway into 2026

\$351M cash at end of 2022



Time Domain Sequencing™

Novel method sequences peptides at the amino acid level in a massively parallel fashion on a semiconductor chip

>1,000

Patents issued & applications pending

Peer-Reviewed Technology

Published in *Science* in October 2022




Launched Platinum™, the world's first next-generation single-molecule protein sequencing platform, in December 2022

Shipping underway, **expect to book revenue in 1Q23**

Proteomics market opportunity valued at **\$75B+**¹



Unlocking the Value of the Proteome



Proteins are the main structural and functional components of cells and they are extremely diverse

Protein modifications are real-time indicators of health and disease, making them ideal markers for disease, drug response and health


85% of the **human proteome** is currently undrugged¹, potential for game changing drug development

Next-generation, single-molecule protein sequencing provides an unbiased view of amino acid mutations and post-translational modifications (PTMs) that can be missed by affinity-based methods


1. Chemical & Engineering News, "A Quest to Drug the Undruggable", June 20, 2018

Large and Growing Market Opportunity

\$75B+ Proteomics Market¹



\$8B+ Initial Target Market²



The Quantum-Si Solution



Sample Prep

CARBON™ (Launching in 2023)

Universal cartridge based sample preparation and automation



Sequencing & Cloud Analysis

PLATINUM™

Massively Parallel, Single Molecule Detection



Reagents & Chips

CONSUMABLES

Library Prep & Protein Sequencing


Disruptive Technology

Accessible Design


Proven Team & Technology




Quantum-Si's Technology: Time Domain Sequencing



Massively parallel analysis on a semiconductor chip




Single molecule sequencing reactions in independent wells



Beyond color with Time Domain Sequencing

Proprietary Amino Acid Recognizers Deliver Industry Leading Proteome Coverage




- World class protein engineering and directed evolution program in-house
- Recognition of 15 out of 20 amino acids
- Path to >70% coverage of the human proteome
- Identification of up to 90% of proteins, as well as a greater understanding of protein sequence variation and post-translational modifications (PTMs)
- Working to further increase proteome coverage in 2023



Post-Translational Modifications: See What Others Can't

- **Single-molecule binding kinetics** enables the detection of PTMs without the need to develop new affinity reagents (no *a priori* knowledge is needed)
- ADMA and SDMA have **distinct kinetic signatures** despite having identical mass (these two PTMs are unlikely to be distinguished by mass spec)
- Quantum-Si technology can unlock the ability to study complex disease pathways and discover novel biomarkers




Drug Targets that Modify Proteoforms are Driving M&A Deal Value

- Kinases are drug targets that phosphorylate proteins to generate proteoforms
- \$100B in deal value for Kinase inhibitors in the last decade - represents 37% of the total Pharma/Biotech M&A value¹
- Blockbuster drugs include kinase inhibitors for leukemias (CLL/SLL), melanoma, and other cancers

Example for CLL (chronic lymphocytic leukemia):

BTK is a Kinase that activates B-Cell proliferation by phosphorylating a protein (PLCG2)



Accessible to Any Lab, Anywhere



Proteins

Library Prep

Load Chip

Sequence

Data Analysis

Benchtop instrument;
User installable

Low capital cost

Leverages standard
laboratory workflow

Simplified and
automated data
analysis




Quantum-Si Cloud™ - Automated Data Analysis

Cloud-based analysis software delivers high quality peptide calls that are automated and easy to interpret

Data from Mass Spectrometry Core Lab

Mass Spec ID Report															
AutoSave OFF															
Home Insert Draw Page Layout Formulas Data Review View Automate Tell me															
Calibri 10 A A Wrap Text General Conditional Formatting Format as Table Cell Styles Insert Delete Format															
A27 X ✓ fx															
	A	B	C	D	E	F	G	H	I	J	K	L	M	N	O
	Master Protein	Accession	Description	Contaminant	Coverage	% # Peptides	# PSMs	# Unique Peps	# AAs	MW (kDa)	calc. pI	Score	Sequent HT	# Peptides (By Search Engine)	# Peptides (By Search Engine)
1	Master Protein	Q6H4M0	Cerebral dopamine neurotrophic factor OS=Homo sapiens GN=CDNF PE=1 SV=2	FALSE	76	25	506	15	187	21	7.55	407.45	25	15	202.78
2	Master Protein	Q6H4H2	Isomorph 2 of Cerebral dopamine neurotrophic factor OS=Homo sapiens GN=CDNF	FALSE	72	11	140	1	85	9.8	7.8	416.96	1	10	11.13
3	Master Protein	P53999	Activated RNA polymerase II transcriptional coactivator p15 OS=Homo sapiens GN=SUH1 PE=1 SV=3	FALSE	29	4	7	4	127	14.4	9.6		4		20
4	Master Protein	P15402	Histone H1.3 OS=Homo sapiens GN=H1.3 PE=1 SV=2	FALSE	25	5	13	4	221	22.3	11.02	20.14	5	4	36.15
5	Master Protein	P11142	Heat shock cognate 71 kDa protein OS=Homo sapiens GN=HSP70 PE=1 SV=1	FALSE	22	11	16	11	646	70.9	5.52	12.44	11	4	52.54
6	Master Protein	P15401	Histone H1.5 OS=Homo sapiens GN=H1.5 PE=1 SV=3	FALSE	17	3	5	2	226	22.6	10.92	9.58	2	3	14.39
7	Master Protein	P67809	Y-box binding protein 1 OS=Homo sapiens GN=YBX1 PE=1 SV=3	FALSE	16	3	6	3	324	35.9	9.88	10.17	3	2	26.28
8	Master Protein	P13645	Keratin, type I cytoskeletal 10 OS=Homo sapiens GN=KRT10 PE=1 SV=6	FALSE	8	3	6	3	584	58.8	5.21	5.88	3	2	15.76
9	Master Protein	P61254	60S ribosomal protein L26 OS=Homo sapiens GN=RPL26 PE=1 SV=1	FALSE	8	1	2	1	145	17.2	10.55	2.75	1	1	3.21
10	Master Protein	P02765	Alpha-2-HS glycoprotein OS=Homo sapiens GN=AHSG PE=1 SV=2	FALSE	7	3	6	3	367	39.3	5.72	6.31	3	1	10.08
11	Master Protein	Q9H3W5	Leucine-rich repeat neuronal protein 3 OS=Homo sapiens GN=LRNP3 PE=2 SV=1	FALSE	6	5	8	5	708	79.4	7.83	2.6	5	1	17.7
12	Master Protein	P02533	Keratin, type I cytoskeletal 14 OS=Homo sapiens GN=KRT14 PE=1 SV=4	FALSE	6	2	3	2	472	51.5	5.16	4.54	2	1	6.26
13	Master Protein	P07185	Histone H1.0 OS=Homo sapiens GN=H1.0 PE=1 SV=3	FALSE	5	1	1	1	194	20.9	10.84		1		2.71
14	Master Protein	Q9N094	Neurogranin OS=Homo sapiens GN=NG2 PE=1 SV=1	FALSE	4	2	2	2	816	91.9	6.21		2		10.98
15	Master Protein	P53145	Mesencephalic astrocyte-derived neurotrophic factor OS=Homo sapiens GN=MANF PE=1 SV=3	FALSE	4	1	1	1	182	20.7	8.69		1		4.14
16	Master Protein	C15031	Plen-R2 OS=Homo sapiens GN=PLEN2 PE=1 SV=3	FALSE	3	3	4	3	1838	205	6.24	4.48	3	1	8.25
17	Master Protein	P63267	Actin, gamma-enteric smooth muscle OS=Homo sapiens GN=ACTG2 PE=1 SV=1	FALSE	3	1	2	1	376	41.9	5.48	0	1	1	3.9
18	Master Protein	P49226	Malate dehydrogenase, mitochondrial OS=Homo sapiens GN=MDH2 PE=1 SV=3	FALSE	3	1	1	1	338	35.5	8.68	2.71	1	1	1.07
19	Master Protein	P187006	*CONY ReckName: Full-length endopeptidase; AltName: Full-length regulated endopeptidase; Flag	FALSE	3	1	1	1	462	48.2	6.95	3.48		1	
20	Master Protein	Q72385	Usher domain-containing protein ARMC3 OS=Homo sapiens GN=ARMC3 PE=1 SV=3	FALSE	2	2	14	2	818	91.8	6.2		2		5.04
21	Master Protein	Q72641	THAP domain-containing protein 5 OS=Homo sapiens GN=THAP5 PE=1 SV=2	FALSE	2	1	1	1	395	45.4	6.71		1		2.62
22	Master Protein	Q14688	Zinc finger protein 234 OS=Homo sapiens GN=ZFP234 PE=2 SV=3	FALSE	2	1	1	1	700	80.5	6.63	2.24		1	
23	Master Protein	Q13061	Tridrin OS=Homo sapiens GN=TRIDN PE=1 SV=4	FALSE	1	1	1	1	729	81.5	9.42	1.72		1	

Data from the Quantum-Si Cloud




Quantum-Si is Differentiated from the Competition

	Quantum-Si	Encodia	Erisyon	Nautilus	SomaLogic	Olink
Commercially Available	✓	X	X	X	✓	✓
Technology	Direct kinetic sequencing	Binding + Degradation with NGS readout	Labeling + Degradation with scanning	Aptamers/Antibodies	Aptamers	Antibodies
Instrument Cost	\$	\$\$\$*	\$\$	\$\$\$	\$\$-\$\$\$**	\$-\$\$\$**
Run Cost	\$	\$\$-\$\$\$*	\$\$	\$\$-\$\$\$	\$\$-\$\$\$**	\$-\$\$\$**
AA Sequencing	✓	Limited	Limited	X	X	X
PTM Detection	✓	?	Requires special reagent	?	Requires PTM specific reagent development	
Automated Data Analysis	✓	?	?	?	?	?




Quantum-Si is Leading the Protein Sequencing Revolution

The analog to digital transition creates new market opportunities – we have seen this before




Commercial Priorities in 2023



Positive Initial Customer and Market Feedback

- Customers across a wide range of market segments are advancing through the sales process
- Initial application interests include proteoforms and PTM's, protein identification and peptide barcoding
- Customers have been able to successfully install Platinum



Facilitating Adoption via Proof-of-Concept Testing Service



Customer sends
samples and pays a
modest fee

Quantum-Si
sequences samples

Data is analyzed
and reported to
customer

Customer
purchases Platinum



Quantum-Si is Well-Positioned for a Successful 2023



Commercialize Platinum, Carbon and 2M Chip

→ Fulfill Platinum demand; Ensure a positive customer experience; Generate data and publications; Carbon beta testing 2Q23, launch 2H23



Lead with Innovation

→ Deliver new data analysis tools; Expand proteome coverage; Drive partnerships and collaborations



Preserve Financial Strength

→ Extend cash runway into 2026; Continued fiscal discipline



The Protein Sequencing Company™

Q&A

